Clinical trials: Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
- Condition Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
- Funder type Industry (pharma, biotech, devices)
Cervical Cancers, Vulvar Cancer
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years.
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT03676101
- Testing
- 9-valent HPV Recombinant Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- NCT03721978
- Testing
- VGX-3100, CELLECTRA™-5PSP
- Where
- 53 sites in United States, Argentina and 8 more
- Volunteers
- 203 people
- Sponsor
- Inovio Pharmaceuticals
Papillomavirus Infections
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
DNA vaccines, which are small pieces of DNA also known as plasmids, have several advantages over traditional vaccines such as live attenuated virus and recombinant protein-based vaccines.
- Trial name
- NCT00685412
- Testing
- VGX-3100
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 18 people
- Sponsor
- Inovio Pharmaceuticals
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- TG-003 (NCT00596258)
- Testing
- A-007
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Tigris Pharmaceuticals
Uterine Cervical Neoplasia, Cervix Intraepithelial Neoplasia
Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3)
The purpose of this phase-II study is to evaluate the efficacy and safety of an aqueous gel containing an antiviral, administered directly on cervix exhibiting high grade squamous or glandular intraepithelial lesion (CIN 2 and 3)…
- Trial name
- Colvir-PhaseII (NCT01303328)
- Testing
- C1
- Where
- 9 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- Mithra Pharmaceuticals
Cervical Cancer, Precancerous Condition
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in…
- Trial name
- NCT00128661
- Testing
- human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, hepatitis A inactivated virus vaccine
- Where
- Costa Rica
- Volunteers
- 7,466 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
The primary purpose of the study is to determine if GARDASIL™ (V501) is able to prevent cervical cancer.
- Trial name
- FUTURE II (NCT00092534)
- Testing
- Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 12,167 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Vulvar Cancer
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04422366
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®
- Where
- China
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Intraepithelial Neoplasia
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
This is randomized, placebo controlled study to determine safety and efficacy of VGX-3100 DNA Vaccine delivered by Electroporation to adult women with biopsy-proven HPV 16 or 18 associated Cervical intraepithelial neoplasia grade…
- Trial name
- HPV-003 (NCT01304524)
- Testing
- VGX 3100, CELLECTRA™-5P
- Where
- 43 sites in United States, Australia and 7 more
- Volunteers
- 167 people
- Sponsor
- Inovio Pharmaceuticals
Human Papillomavirus Associated Intraepithelial Neoplasia, Cervical Intraepithelial Neoplasia Grade 2/3
A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3
The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).
- Conditions
- Human Papillomavirus Associated Intraepithelial Neoplasia, Cervical Intraepithelial Neoplasia Grade 2/3, Human Papillomavirus Type 16 Infection, Human Papillomavirus Type 18 Infection
- Trial name
- NCT06273553
- Testing
- RG002 injection
- Volunteers
- 39 people
- Sponsor
- RinuaGene Biotechnology Co., Ltd.
High Grade Cervical Intraepithelial Neoplasia
IMproved PRactice Outcomes and Value Excellence in Colposcopy
The study will observe and quantify shifts in colposcopy practice and outcome improvements in U.S. community-based cervical screening colposcopy examinations after the introduction of the DySIS colposcope with Advanced Cervical…
- Trial name
- IMPROVE-COLPO (NCT02185599)
- Testing
- DySIS
- Where
- 46 sites in United States
- Volunteers
- 7,555 people
- Sponsor
- DySIS Medical Inc.
High Grade Cervical Intraepithelial Neoplasia
An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)
This is an exploratory, open, prospective multi-centre study of VB10.16 immunotherapy in patients with high grade HPV16+ Cervical Intraepithelial Neoplasia (HSIL; CIN2/3).
- Trial name
- NCT02529930
- Testing
- VB10.16 Immunotherapy (DNA vaccine)
- Where
- 4 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Nykode Therapeutics ASA
CIN2
Performance of Tampons as a Biospecimen Collection Tool for the Detection of Human Papillomavirus in a Colposcopy Setting
Evaluation of the clinical performance of the Daye Diagnostic Tampon (DDT) for the detection of Human Papilloma Virus (HPV) infection associated with high grade cervical disease.
- Trial name
- PETAHG (NCT06210074)
- Testing
- Daye Diagnostic Tampon
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Tampon Innovations Ltd
Cervical Intraepithelial Neoplasia Grade 2/3
The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection
The FRDTM is easy to perform and does not require sophisticated laboratory technology and/or experienced pathologists for test result interpretation.
- Trial name
- NCT03366493
- Testing
- FRD, Cytology, HPV testing
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GY Highland Biotech LLC
HPV Infection
Study of FluBHPVE6E7 in HPV-16 Infected Women
BS-01 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study assessing safety, tolerability and immunogenicity of FluBHPVE6E7, changes in the HPV infection status and cervical cytology, and…
- Trial name
- NCT04490512
- Testing
- FluBHPVE6E7
- Where
- Austria
- Volunteers
- 28 people
- Sponsor
- BlueSky Immunotherapies GmbH
Cervical Intraepithelial Neoplasia
A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection
This randomized, double-blind, placebo-controlled, parallel arm study will assess the safety and the efficacy of RO5217790 on histologic resolution in participants with high grade CIN associated with HR-HPV infection.
- Trial name
- NCT01022346
- Testing
- RO5217790
- Where
- 66 sites in United States, Belgium and 4 more
- Volunteers
- 206 people
- Sponsor
- Hoffmann-La Roche
HPV Infections, Cervical Cancer
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT04895020
- Testing
- 9-valent HPV vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Genital Wart
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45…
- Conditions
- Cervical Cancer, Genital Wart, CIN1, CIN2
- Trial name
- NCT05584332
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- China
- Volunteers
- 3,131 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- NCT00285207
- Testing
- A007
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Tigris Pharmaceuticals